MedTrace Logo

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00110162 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2013-08-07

No results posted yet for this study

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens.

PURPOSE: This randomized phase III trial is studying how well androgen deprivation therapy works in treating patients with prostate cancer.

Conditions

Interventions

DRUG

antiandrogen therapy

DRUG

releasing hormone agonist therapy

PROCEDURE

orchiectomy

Sponsors & Collaborators

  • Peter MacCallum Cancer Centre, Australia

    lead OTHER

Principal Investigators

  • Gillian M. Duchesne, MD, FRCR · Peter MacCallum Cancer Centre, Australia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2009-12-31

Countries

  • Australia
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00110162 on ClinicalTrials.gov